tirzepatide indications fda Big update in pediatric diabetes care 🩺 Mounjaro® (tirzepatide) is now FDA-approved for children ≥10 years old with Type 2 diabetes as an adjunct to diet and exercise. What this means ⬇️ Is Tirzepatide FDA Approved?

Monjauro Mounjaro, FDA-approved in 2022 for the treatment of type 2 diabetes, is one of Eli Lillys most widely discussed drugs due to its reported weight loss benefits

Lean tissue accounted for approximately 39% of total weight lost (Wilding et al., NEJM , 2021)

Evidence quality assessment Strong evidence: BPC-157 accelerates tendon healing in rats (multiple independent studies, consistent results, large effect sizes)

Physicians certified by the Canadian Board of Obesity Medicine have completed additional training in the complex biology of weight regulation and the nuances of pharmacological treatment

Tirzepatide Oral Dissolving Tablets have not undergone clinical trials

The research chemical market operates without pharmaceutical-grade manufacturing standards or regulatory oversight